The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women

Journal of Infectious Diseases

Volumn 174, Issue 5, 1996, Pages 927-936

  Carter, Joseph J ^b   Koutsky, Laura A ^b   Wipf, Gregory C ^b   Christensen, Neil D ^b   Lee, Shu Kuang ^b   Kuypers, Jane ^b   Kiviat, Nancy ^b   Galloway, Denise A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY RESPONSE; ARTICLE; COLLEGE STUDENT; CONDYLOMA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; WART VIRUS;

EID: 0029919427     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.5.927     Document Type: Article

References (29)

1. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
2. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995:87:796-802.
4. Xi LF, Demers GW, Koutsky LA, et al. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 1995;172:747-55.
5. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
6. Christensen ND, Kreider JW, Shah KV, Rando RF. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992;73:1261-7.
7. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
8. Suzich JA, Ghim S, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus LI protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
9. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 1994;62:194-8.
10. Hagensee M, Yaegashi N, Galloway DA. Self-assembly of human papillo-mavirus type 1 capsids by expression of the LI protein alone or by coexpression of the LI and L2 capsid proteins. J Virol 1993; 67: 315-22.
11. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89: 12180-4.
12. Carter JJ, Hagensee M, Taflin MC, Lee SK, Koutsky LA, Galloway DA. HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology 1993;195:456-62.
13. Kimbauer R, Hubbert NL, Wheeler CM, Decker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillo-mavirus type-16. J Natl Cancer Inst 1994; 86:494-9.
14. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33 :2058-63.
15. Carter JJ, Wipf GC, Hagensee ME, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11-8.
16. Heim K, Christensen ND, Hoepfl R, et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different patient groups. J Infect Dis 1995; 172:395-402.
17. Heino P, EkLund C, Fredriksson-Shanazarian V, Goldman S, Schiller JT, Dillner J. Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995; 87:437-40.
18. Nonnenmacher B, Hubbert NL, Kirnbauer R, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995; 172:19-24.
19. Rose RC, Bonnez W, Darin C, McCance DJ, Reichman RC. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 1994;75:2445-9.
20. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of serore-activity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995; 172:1425-30.
21. Cubie HA. Serological studies in a student population prone to infection with human papilloma virus. J Hyg 1972;70:677-90.
22. Carter JJ, Hagensee MB, Lee SK, McKnight B, Koutsky LA, Galloway DA. Use of HPV1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology 1994; 199:284-91.
23. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: Furth M, Greaves M, eds. Molecular diagnostics of human cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:209-14 (Cancer cells series; no. 7).
24. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type-16 LI and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
25. Dean RB, Dixon WJ. Simplified statistics for small numbers of observations. Anal Chem 1951;23:636-8.
26. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173:1394-8.
27. Wikstrom A, van Doornum GJ, Quint WG, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995;76: 529-39.
28. Hagensee ME, Carter JJ, Wipf GC, Galloway DA. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 1995;206:174-82.
29. Christensen ND, Hopfl R, DiAngelo SL, et al. Assembled baculovirus-expressed human papillomavirus type 11 LI capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75:2271-6.